A New Class of Immunomodulatory Drugs for Multiple Sclerosis


Multiple sclerosis (MS) is an autoimmune disease caused by activated autoimmune T lymphocytes in patients resulting in inflammatory demyelination in the central nervous system. Current treatments are focused on functional control of these activated autoimmune T cells, but these treatments are non-specific T cell inhibitors and have serious, sometimes fatal side effects. A specific therapy aimed at eliminating these autoimmune T cells through restimulation-induced cell death (RICD) could cure the disease and overcome the fatal side effects of current therapies. NIAID inventors have identified a multi-valent tolerogen (MMPt), which can specifically elicit RICD of the activated, disease causing autoimmune T cells without compromising the general T cell-dependent immunity in the host. Animal studies have demonstrated that MMPt exerts robust therapeutic effects on both monophasic as well as relapsing-remitting type of the disease, indicating its medical applicability for treating MS patients with active disease. NIAID is seeking partners to develop this multi-valent peptide to improve its efficacy for use in clinical trials.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications: Competitive Advantages:
  • Therapeutics
 
  • Tolerogen induced elimination of activated autoimmune T cells will overcome the fatal side effects of current therapies
  • Treatment of all types of MS patients


Inventors:

Michael Lenardo (NIAID)  ➽ more inventions...

Jian Li (NIAID)  ➽ more inventions...

Lixin Zheng (NIAID)  ➽ more inventions...

Jae Won Lee (NIAID)  ➽ more inventions...

Wei Lu (NIAID)  ➽ more inventions...


Intellectual Property:
US Application No. 62/130,285
US Application No. 62/219,851
PCT Application No. PCT/US2016/021571
US Application No. 15/556,738
Various international patent applications may also be available

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the MMPt peptide to improve its efficacy for use in clinical trials. For collaboration opportunities, please contact Yogikala Prabhu, Ph.D.,at prabhuyo@niaid.nih.gov or 301-761-7789.


Licensing Contact:
Yogikala Prabhu,
Email: prabhuyo@niaid.nih.gov
Phone: 301-761-7789

OTT Reference No: E-064-2015-0
Updated: Oct 2, 2018